Cargando…
Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study)
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease that can involve multiple organs or systems. Lupus nephritis (LN) is associated with high mortality and morbidity. However, plenty of patients do not respond to present treatment or relapse. Iguratimod (IGU) is a new small molec...
Autores principales: | Yan, Qingran, Du, Fang, Kang, Yuening, Ye, Ping, Wang, Xiaodong, Xu, Jianhua, Tang, Jianping, Wang, Niansong, Jiang, Gengru, Li, Zhijun, Wang, Xuan, Xue, Qin, Huang, Xinfang, Zhang, Xiaoyan, Zhou, Ying, Dai, Min, Bao, Chunde |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356213/ https://www.ncbi.nlm.nih.gov/pubmed/34380536 http://dx.doi.org/10.1186/s13063-021-05475-3 |
Ejemplares similares
-
Prevention of Immune Nephritis by the Small Molecular Weight Immunomodulator Iguratimod in MRL/lpr Mice
por: Yan, Qingran, et al.
Publicado: (2014) -
Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study
por: Kang, Yuening, et al.
Publicado: (2020) -
Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study
por: Yan, Qingran, et al.
Publicado: (2023) -
Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up
por: Fu, Qiong, et al.
Publicado: (2022) -
Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis
por: Ye, Yan, et al.
Publicado: (2019)